|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00002390 |
|
Date of registration:
|
02/11/1999 |
|
Primary sponsor: |
|
|
Public title:
|
A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients
|
|
Scientific title:
|
A Phase II Randomized, Blinded, Dose-Ranging Multicenter Study to Evaluate the Safety and Efficacy of Different Regimens of 1592U89 Monotherapy Upon Selected Immunological and Virological Markers of HIV-1 Infection in Antiretroviral Therapy-Naive Patients |
|
Date of first enrolment:
|
June 1996 |
|
Target sample size:
|
|
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00002390 |
|
Study type:
|
Interventional |
|
Study design:
|
Masking: Double-Blind, Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
France
|
Germany
| | | | | | |
|
Key inclusion & exclusion criteria
|
|
Health Condition(s) or Problem(s) studied
|
|
HIV Infections
|
|
Intervention(s)
|
|
Drug: Abacavir sulfate
|
|
Secondary ID(s)
|
|
238H
|
|
CNAB2002
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|